Legal & General Group’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.93M | Buy |
103,125
+3,876
| +4% | +$110K | ﹤0.01% | 1808 |
|
|
2025
Q1 | $2.93M | Sell |
99,249
-2,851
| -3% | -$84.2K | ﹤0.01% | 1781 |
|
|
2024
Q4 | $2.97M | Buy |
102,100
+14,111
| +16% | +$410K | ﹤0.01% | 1819 |
|
|
2024
Q3 | $4.04M | Buy |
87,989
+2,784
| +3% | +$128K | ﹤0.01% | 1674 |
|
|
2024
Q2 | $3.48M | Buy |
85,205
+9,156
| +12% | +$374K | ﹤0.01% | 1714 |
|
|
2024
Q1 | $1.94M | Buy |
76,049
+17,214
| +29% | +$439K | ﹤0.01% | 1955 |
|
|
2023
Q4 | $532K | Buy |
58,835
+282
| +0.5% | +$2.55K | ﹤0.01% | 2424 |
|
|
2023
Q3 | $374K | Sell |
58,553
-685
| -1% | -$4.37K | ﹤0.01% | 2547 |
|
|
2023
Q2 | $657K | Buy |
59,238
+29,777
| +101% | +$330K | ﹤0.01% | 2365 |
|
|
2023
Q1 | $452K | Buy |
29,461
+7,291
| +33% | +$112K | ﹤0.01% | 2341 |
|
|
2022
Q4 | $492K | Buy |
22,170
+5,423
| +32% | +$120K | ﹤0.01% | 2344 |
|
|
2022
Q3 | $274K | Sell |
16,747
-2,694
| -14% | -$44.1K | ﹤0.01% | 2504 |
|
|
2022
Q2 | $282K | Buy |
19,441
+725
| +4% | +$10.5K | ﹤0.01% | 2519 |
|
|
2022
Q1 | $345K | Buy |
18,716
+552
| +3% | +$10.2K | ﹤0.01% | 2495 |
|
|
2021
Q4 | $431K | Hold |
18,164
| – | – | ﹤0.01% | 2458 |
|
|
2021
Q3 | $448K | Buy |
18,164
+14,853
| +449% | +$366K | ﹤0.01% | 2443 |
|
|
2021
Q2 | $82K | Sell |
3,311
-590
| -15% | -$14.6K | ﹤0.01% | 2798 |
|
|
2021
Q1 | $85K | Buy |
3,901
+1,259
| +48% | +$27.4K | ﹤0.01% | 2661 |
|
|
2020
Q4 | $68K | Buy |
2,642
+771
| +41% | +$19.8K | ﹤0.01% | 2710 |
|
|
2020
Q3 | $53K | Buy |
+1,871
| New | +$53K | ﹤0.01% | 2677 |
|